abrdn Physical Palladium Shares ETF vs Roivant Sciences Ltd. Common Shares — how do they compare? abrdn Physical Palladium Shares ETF trades at $21.05 (market cap $586.03M), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 42.8× abrdn Physical Palladium Shares ETF's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold abrdn Physical Palladium Shares ETF for 33 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| PALL | ROIV | |
|---|---|---|
Market Cap | $586.03M | $25.09B |
Volume | 1,073,971 | 5,738,571 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.18 | $41.81 |
52-Week Low | $20.30 | $16.04 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | — | $21.36B |
Signals from Pluang's Aura AI — not financial advice
PALL (Aberdeen Physical Palladium Shares ETF) trades at $20.30, down 4.47% with bearish technical signals from moving averages but bullish RSI readings. The ETF tracks palladium prices, which have declined 47% from January 2026 highs. Recent news highlights palladium's underperformance versus gold and silver, with some analysts viewing current levels as a buying opportunity given supply risks and industrial demand.
PALL presents a contrarian opportunity as palladium approaches technical support levels, though the metal faces headwinds from automotive sector volatility. The ETF's value depends entirely on palladium price movements rather than company fundamentals, creating pure commodity exposure with significant price volatility risk.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →